The emergence of trastuzumab deruxtecan has led to significant improvement in clinical outcomes for patients with HER2-low metastatic breast cancer, which accounts for approximately half (45%–55%) of breast cancer diagnoses. This evidence concerns the gene ERBB2 and breast carcinoma.